Healthy men swallow radioactive drug to reveal its journey through the body
NCT ID NCT07036458
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 1 study gave 8 healthy men a single dose of radioactive-labelled epaminurad to track how the drug is absorbed, broken down, and eliminated in urine and feces. The goal was purely scientific — to understand the drug's metabolism and recovery — not to treat any disease. No health benefits were expected for participants.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Epaminurad (radioactive-labelled oral solution)
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
8 people
The number who actually took part.
- Started
-
Aug 2025
- Finished
-
Sep 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
30 to 65 years
- Sex
-
Male participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1\. Healthy volunteers Exclusion Criteria: 1\. Subjects does not meet the Inclusion Criteria
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy male adults are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Quotient Science
Nottingham, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.